Finally, the authors observed that BCR activity in CLL represses miR-29 and its inhibition by therapeutic agents, such as Ibrutinib or Idelalisib, increases levels of miR-29 and consequently decreases levels of TRAF4 [51]. Here, BCR is linked to B-cell chronic lymphocytic leukemia.